◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Cipla Limited (CIPLA) Revenue 2023–TTM

Name: Cipla Limited (CIPLA) revenue history 2023-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-11-01

Cipla Limited annual revenue for fiscal TTM was ₹278.7 billion, an increase of 0.6% from ₹277.1 billion in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

CIPLA Annual Revenue

Revenue (annual)	TTM → 2026-09-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹278.7B	₹277.1B	₹271.5B	₹254.5B	₹224.7B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CIPLA Quarterly Revenue

Revenue (quarterly)	2026-09-30	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Total Revenue	₹73.7B	₹70.8B	₹64.6B	₹69.6B	—	₹68.4B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

4151 Revenue — Kyowa Kirin Co., Ltd.
LAURUSLABS Revenue — Laurus Labs Limited
ZYDUSLIFE Revenue — Zydus Lifesciences Limited
DRREDDY Revenue — Dr. Reddy's Laboratories Limited
AUROPHARMA Revenue — Aurobindo Pharma Limited
MANKIND Revenue — Mankind Pharma Limited

More CIPLA metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All CIPLA financial statements → Interactive CIPLA charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.